Phase I trial of subcutaneous interleukin 3 in patients with refractory malignancy: Hematological, immunological, and pharmacodynamic findings

Clinical Cancer Research

Volumn 2, Issue 2, 1996, Pages 347-357

  Bukowski, Ronald M ^a,b   Olencki, Thomas ^a,b   Gunn, Han ^c   McLain, Denise ^b   Budd, G Thomas ^a   Sandstrom, Kate ^b   Tuason, Laurie ^a   Redovan, Christine ^a   Rayman, Patricia ^a   Tubbs, Raymond ^a   Resta, Debra ^c   Elson, Paul ^a   Finke, James ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c Sandoz Pharma Ltd   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2 RECEPTOR; RECOMBINANT INTERLEUKIN 3;

ADULT; AGED; ARTICLE; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; FEVER; HEADACHE; HUMAN; MYALGIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; BLOOD CELL COUNT; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-3; INTERLEUKIN-6; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NEOPLASMS; RECEPTORS, INTERLEUKIN-2; RECOMBINANT PROTEINS;

EID: 9044247457     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Ihle, J. N., Keller, J., Oroszlan, S., Henderson, L. E., Copeland, T. D., Fitch, F., Prystowsky, M. B., Goldwasser, E., Schrader, J. W., Palaszynski, E., Dy, M., and Lebel, B. Biologic properties of homogenous interleukin 3. I. Demonstration of WEHI-3 growth factor activity, mast cell growth factor activity, p cell-stimulating factor activity, colony-stimulating factor activity, and histamine-producing cell-stimulating factor activity. J. Immunol., 131: 282-287, 1983.
2. Ihle, J. N., Pepersack, L., and Rebar, L. Regulation of T cell differentiation: in vitro induction of 20 α-hydroxysteroid dehydrogenase in splenic lymphocytes from athymic mice by a unique lymphokine. J. Immunol., 126: 2184-2189, 1981.
3. Leary, A. G., Yang, Y. C., Clark, S. C., Gasson, J. C., Golde, D. W., and Ogawa, M. Recombinant gibbon interleukin 3 supports formation of human multilineage colonies and blast cell colonies in culture: comparison with recombinant human granulocyte-macrophage colony-stimulating factor. Blood, 70: 1343-1348, 1987.
4. Sonoda, Y., Yang, Y. C., Wong, G. G., Clark, S. C., and Ogawa, M. Analysis in serum-free culture of the targets of recombinant human hematopoietic growth factors: interleukin 3 and granulocyte-macrophage colony-stimulating factor are specific for early developmental stages. Proc. Natl. Acad. Scii. USA, 85: 4360-4364, 1988.
5. Lopez, A. F., To, L. B., Yang, Y. C., Gamble, J. R., Shannon, M. F., Burns, G. F., Dyson, P. G., Juttner, C. A., Clark, S., and Vadas, M. A. Stimulation of proliferation, differentiation, and function of human cells by primate interleukin 3. Proc. Natl. Acad. Sci. USA. 84: 2761-2765, 1987.
6. Gillis, S., Urdal, D. L., Clevenger, W., Klinke, R., Sassenfield, H., Price, V., and Cosman, D. Production of recombinant human colony stimulating factors in yeast. Behring Inst. Mitt., 83: 1-7, 1988.
7. Lokker, N. A., Movva, N. R., Strittmatter, U., Fagg, B., and Zenke, G. Structure-activity relationship study of human interleukin-3. Identification of residues required for biological activity by site-directed mutagenesis. J. Biol. Chem., 266: 10624-10631, 1991.
8. +, 2-T cells with purified interleukin 3. Cell. 25: 179-186, 1981.
9. Santoli, D., Clark, S. C., Kreider, B. L., Maslin, P. A., and Rovera, G. Amplification of EL-2-driven T cell proliferation by recombinant human IL-3 and granulocyte-macrophage colony-stimulating factor. J. Immunol., 141: 519-526, 1988.
10. Onishi, R., Ishikawa, T., Kodaka, T., Okuma, M., and Uchiyama, T. Interleukin-3-induced downregulation of the expression of interleukin-2 receptor β chain in human T cells. Blood. 78: 2908-2917, 1991.
11. Cannistra, S. A., Vellenga, E., Groshek, P., Rambaldi, A., and Griffin, J. D. Human granulocyte-monocyte colony-stimulating factor and interleukin-3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism. Blood, 71: 672-676, 1988.
12. Thomassen, M. J., Antal, J., Connors, M. J., McLain, D., Sandstrom, K., Meeker, D. P., Budd, G. T., Levitt, D., and Bukowski, R. M. Immunomodulatory effects of recombinant interleukin-3 treatment on human alveolar macrophages and monocytes. J. Immunother., 14: 43-50, 1993.
13. Budd, G. T., Murthy, S., Finke, J., Sergi, J., Gibson, V., Medendorp, S., Barna, B., Boyett, J., and Bukowski, R. M. Phase I trial of high-dose bolus interleukin-2 and interferon α-2a in patients with metastatic malignancy. J. Clin. Oncol., 10: 804-809, 1992.
14. Finke, J. H., Rayman, P., Alexander, J., Edinger, M., Tubbs, R. R., Connelly, R., Pontes, E., and Bukowski, R. Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma. Cancer Res., 50: 2363-2370, 1990.
15. Tubbs, R. R., and Sheibani, K. Immunohistology of lymphoproliferative disorders. Semin. Diagn. Pathol. 1: 272-284, 1984.
16. D3 monoclonal antibody in combination with interferon-α in patients with malignant melanoma. J. Biol. Response Modif., 9: 319-328, 1990.
17. Kruskal, W. H., and Wallis, W. A. Use of ranks on one-criterion variance analysis. J. Am. Stat. Assoc., 47: 583-621, 1952.
18. Hollander, M., and Wolfe, D. Nonparametric Statistical Methods. New York: John Wiley & Sons, Inc., 1973.
19. Spearman, C. The proof and measurement of association between two things. Am. J. Psychol., 15: 72-101, 1904.
20. Payne, R. B., Carver, M. E., and Morgan, D. B. Interpretation of serum total calcium: effects of adjustment for albumin concentration on frequency of abnormal values and on detection of change in the individual. J. Clin. Pathol. (Lond.), 32: 56-60, 1979.
21. Hirai, K., Monta, Y., Misaki, Y., Ohta, K., Takaishi, T., Suzuki, S., Motoyoshi, K., and Miyamoto, T. Modulation of human basophil histamine release by hemopoietic growth factors. J. Immunol, 141: 3958-3964, 1988.
22. MacDonald, S. M., Schleimer, R. P., Kagey-Sobotka, A., Gillis, S., and Lichtenstein, L. M. Recombinant IL-3 induces histamine release from human basophils. J. Immunol, 142: 3527-3532, 1989.
23. Lindemann, A., Ganser, A., Herrmann, F., Frisch, J., Seipelt, G., Schulz, G., Hoelzer, D., and Mertelsmann, R. Biologic effects of recombinant human interleukin-3 in vivo. J. Clin. Oncol., 9: 2120-2127, 1991.
24. Okayama, Y., Begishvili, T. B., and Church, M. K. Comparison of mechanisms of IL-3 induced histamine release and IL-3 priming effect on human basophils. Clin. Exp. Allergy, 23: 901-910, 1993.
25. Merget, R. D., Maurer, A. B., Koch, U., Ganser, A., Ottmann, O. G., Schultze-Werninghaus, G., Seipelt, G., Zachgo, W., Hoelzer, D., and Meier-Sydow, J. Histamine release from basophils after in vivo application of recombinant interteukin-3 in man. Int. Arch. Allergy Appl. Immunol., 92: 366-374, 1990.
26. Ganser, A., Lindemann, A., Seipelt, G., Ottmann, O. G., Herrmann, F., Eder, M., Frisch, J., Schulz, G., Mertelsmann, R., and Hoelzer, D. Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure. Blood, 76: 666-676, 1990.
27. Biesma, B., Willemse, P. H., Mulder, N. H., Sleijfer, D. T., Gietema, J. A., Mull, R., Limburg, P. C., Bouma, J., Vellenga, E., and de Vries, E. G. Effects of interleukin-3 after chemotherapy for advanced ovarian cancer. Blood, 80: 1141-1148, 1992.
28. Rusthoven, J. J., Eisenhauer, E., Mazurka, J., Hirte, H., O'Connell, G., Muldal, A., Lu, H. X., Onetto, N., Swenerton, K., and Jeffrey, J. Phase I clinical trial of recombinant human interleukin-3 combined with carboplatin in the treatment of patients with recurrent ovarian carcinoma. J. Natl. Cancer Inst., 85: 823-825, 1993.
29. Postmus, P. E., Gietema, J. A., Damsma, O., Biesma, B., Limburg, P. C., Vellenga, E., and de Vries, E. G. Effects of recombinant human interleukin-3 in patients with relapsed small-cell lung cancer treated with chemotherapy: a dose finding study. J. Clin. Oncol., 10: 1131-1140, 1992.
30. Kurzrock, R., Talpaz, M., Estrov, Z., Rosenblum, M. G., and Gutterman, J. U. Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. J. Clin. Oncol., 9: 1241-1250, 1991.
31. D'Hondt, V., Weynants, P., Humblet, Y., Guillaume, T., Canon, J. L., Beauduin, M., Duprez, P., Longueville, J., Mull, R., Chatelain, C., and Symann, M. Dose dependent interleukin-3 stimulation of chrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: a placebo-controlled randomized phase Ib study. J. Clin. Oncol., 11: 2063-2071, 1993.
32. Nemunaitis, J., Appelbaum, F. R., Singer, J. W., Lilleby, K., Wolff, S., Greer, J. P., Bierman, P., Resta, D., Campion, M., Levitt, D., Zeigler, Z., Rosenfeld, C., Shadduck, R. K., and Buckner, C. D. Phase I trial with recombinant human interleukin-3 in patients with lymphoma undergoing autologous bone marrow transplantation. Blood, 82: 3273-3278, 1993.
33. Weber, J., Yang, J. C., Topalian, S. L., Parkinson, D. R., Schwartzentruber, D. S., Ettinghausen, S. E., Gunn, H., Mixon, A., Kim, H., Cole, D., Levin, R., and Rosenberg, S. A. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J. Clin. Oncol., 11: 499-506, 1993.
34. Maurer, A. B., Gansen, A., Buhl, R., Seipelt, G., Ottmann, O. G., Mentzel, U., Geissler, R. G., and Hoelzer, D. Restoration of impaired cytokine secretion from monocytes of patients with myelodysplastic syndromes after in vivo treatment with GM-CSF or IL-3. Leukemia (Baltimore), 11: 1728-1733, 1993.
35. Hovgaard, D. J., Folke, M., Mortensen, B. T., and Nissen, N. I. Recombinant human interleukin-3: pharmacokinetics after intravenous and subcutaneous bolus injection and effects on granulocyte kinetics. Br. J. Haematol., 87: 700-707, 1994.
36. Biesma, B., Pokorny, R., Kovarik, J. M., Duffy, F. A., Willemse, P. H., Mulder, N. H., and de Vries, E. G. Pharmacokinetics of recombinant human interleukin-3 administered subcutaneously and by continuous intravenous infusion in patients after chemotherapy for ovarian cancer. Cancer Res. 53: 5915-5919, 1993.
37. Pulaski, B. A., McAdam, A. J., Hutter, E. K., Biggar, S., Lord, E. M., and Frelinger, J. G Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism. Cancer Res., 53: 2112-2117, 1993.
38. 2) cyclophosphamide cancer therapy. Ann. Oncol., 4: 759-766, 1993.
39. Hoffman, R. Interleukin-3: a potentially useful agent for treating chemotherapy-related thrombocytopenia. J. Clin. Oncol., 11: 2057-2060, 1993.